Stentys touts study data showing that its self-apposing drug-eluting stent has merit as a treatment for the booming peripheral artery disease market.
Stentys is touting clinical trial data backing the use of a drug-eluting version of its self-apposing stent for an indication beyond heart attacks: The booming peripheral artery disease market.
Here's a look at some of the top legal news stories for medical device companies this week: Former Medtronic worker sues company, police over arrest in bomb threat hoax; Plaintiffs to J&J on fraud claims: Prove it; Supremes send patent cases back to appeals court
Medtronic says its Cardiocom patient monitoring services business inked another deal with a home health provider, LHC Group, for its Commander Flex telehealth platform.
Johnson & Johnson's DePuy Synthes Spine unit wins expanded FDA clearance for its Synapse screw-rod posterior fixation system, designed to help stabilize the spine following fusion surgery or treatment for certain spinal tumors.
Investors punish Staar Surgical's stock after it warns that 4th-quarter and full-year revenues will miss expectations.
The FDA approves 2 new algorithms for AliveCor's electrocardiogram app.
AliveCor said the FDA approved 2 new algorithms for its eponymous heart monitoring app, which is designed to detect abnormal heart rhythms using a single-channel electrocardiogram.
Medtronic touts a pair of large studies of its 'SmartShock' cardiac rhythm management technology, designed to help reduce inappropriate shocks in defibrillator patients.
